Constellation Investments’s Vertex Pharmaceuticals VRTX Stock Holding History

Constellation Investments’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	$940K	Buy	11,825 +225	+2%	+$20.4K	0.17%	127
2015 Q4	$1.46M	Buy	11,600 +175	+2%	+$21.1K	0.27%	81
2015 Q3	$1.19M	Buy	11,425 +150	+1%	+$19.3K	0.25%	88
2015 Q2	$1.39M	Buy	11,275 +175	+2%	+$22.1K	0.27%	85
2015 Q1	$1.31M	Buy	11,100 +325	+3%	+$38.9K	0.25%	89
2014 Q4	$1.28M	Buy	10,775 +475	+5%	+$53.5K	0.26%	88
2014 Q3	$1.16M	Buy	10,300 +125	+1%	+$11.9K	0.26%	89
2014 Q2	$963K	Sell	10,175 -50	-0.5%	-$3.51K	0.22%	105
2014 Q1	$723K	Buy	10,225 +525	+5%	+$41.6K	0.18%	133
2013 Q4	$721K	Buy	9,700 +650	+7%	+$45.3K	0.18%	127
2013 Q3	$686K	Buy	9,050 +4,575	+102%	+$364K	0.21%	111
2013 Q2	$357K	Buy	+4,475	New	+$330K	0.12%	194

Other funds holding VRTX

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Constellation Investments's VRTX Position: Q1 2016 in Review

Constellation Investments increased its Vertex Pharmaceuticals (VRTX) stake by 1.9% in Q1 2016, buying an estimated $20.4K and bringing the position to 11,825 shares worth $940K. The position accounts for 0.17% of the portfolio, ranked #127.

Constellation Investments first reported a position in VRTX in Q2 2013 and has held it in 12 quarters since. The position peaked at $1.46M in Q4 2015. 503 funds tracked by Wall St. Rank hold VRTX as of Q1 2016.

Constellation Investments held 11,825 shares of Vertex Pharmaceuticals worth $940K as of Q1 2016.
Constellation Investments bought 225 Vertex Pharmaceuticals shares in Q1 2016, an estimated $20.4K.
Vertex Pharmaceuticals made up 0.17% of Constellation Investments's portfolio in Q1 2016, its #127 holding.
Constellation Investments first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 12 quarters since.
Constellation Investments's Vertex Pharmaceuticals position peaked at $1.46M in Q4 2015.
503 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2016.

Based on Constellation Investments's 13F filing for Q1 2016, filed 28 Apr 2016.